• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Significance of Alectinib-Induced Bradycardia: Rhythm and Reversibility Matter More Than Rate.

作者信息

Kondapalli Lavanya, Camidge D Ross

机构信息

Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA.

Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado, USA.

出版信息

JACC CardioOncol. 2023 Feb 21;5(1):114-116. doi: 10.1016/j.jaccao.2022.12.002. eCollection 2023 Feb.

DOI:10.1016/j.jaccao.2022.12.002
PMID:36875893
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9982281/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe9/9982281/67f3ed945369/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe9/9982281/67f3ed945369/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe9/9982281/67f3ed945369/fx1.jpg

相似文献

1
Significance of Alectinib-Induced Bradycardia: Rhythm and Reversibility Matter More Than Rate.阿来替尼所致心动过缓的意义：节律和可逆性比心率更重要。
JACC CardioOncol. 2023 Feb 21;5(1):114-116. doi: 10.1016/j.jaccao.2022.12.002. eCollection 2023 Feb.
2
Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up.阿来替尼对ALK阳性肺癌患者的心脏毒性：心脏肿瘤学随访结果
JACC CardioOncol. 2023 Jan 17;5(1):102-113. doi: 10.1016/j.jaccao.2022.09.006. eCollection 2023 Feb.
3
High incidence and reversible bradycardia events following alectinib initiation.阿来替尼起始治疗后高发且可逆转的心动过缓事件。
Thorac Cancer. 2023 Feb;14(5):479-488. doi: 10.1111/1759-7714.14769. Epub 2022 Dec 19.
4
ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.真实世界中 ALK 阳性非小细胞肺癌患者的 ALK 抑制剂治疗模式和结局：一项回顾性队列研究。
Target Oncol. 2023 Jul;18(4):571-583. doi: 10.1007/s11523-023-00973-7. Epub 2023 Jun 21.
5
Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies.阿来替尼对心脏电生理学的影响：来自关键II期NP28761和NP28673研究的强化心电图监测结果。
Cancer Chemother Pharmacol. 2017 Mar;79(3):559-568. doi: 10.1007/s00280-017-3253-5. Epub 2017 Feb 27.
6
ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis.ALK 抑制剂所致心动过缓：系统评价和荟萃分析。
Lung Cancer. 2021 Nov;161:9-17. doi: 10.1016/j.lungcan.2021.08.014. Epub 2021 Aug 31.
7
Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC.晚期 NSCLC 患者因阿来替尼导致的有症状心动过缓。
Acta Med Indones. 2022 Apr;54(2):303-306.
8
Comparison of Clinical Efficacy of Alectinib Crizotinib in -Positive Non-Small Cell Lung Cancer: A Meta-Analysis.阿来替尼与克唑替尼治疗ALK阳性非小细胞肺癌的临床疗效比较：一项荟萃分析。
Front Oncol. 2021 Jun 2;11:646526. doi: 10.3389/fonc.2021.646526. eCollection 2021.
9
Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy.阿来替尼治疗ALK阳性非小细胞肺癌：其特性、疗效、安全性及治疗地位的最新进展
Ther Adv Med Oncol. 2018 Aug 3;10:1758835918789364. doi: 10.1177/1758835918789364. eCollection 2018.
10
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.识别晚期 ALK 阳性非小细胞肺癌一线和二线治疗中最优的 ALK 抑制剂：系统评价和网络荟萃分析。
BMC Cancer. 2024 Feb 8;24(1):186. doi: 10.1186/s12885-024-11916-4.

引用本文的文献

1
Lung Cancer and Cardiovascular Disease: Common Pathophysiology and Treatment-Emergent Toxicity.肺癌与心血管疾病：共同的病理生理学与治疗——新发毒性
JACC CardioOncol. 2025 Jun;7(4):325-344. doi: 10.1016/j.jaccao.2025.05.003.

本文引用的文献

1
Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up.阿来替尼对ALK阳性肺癌患者的心脏毒性：心脏肿瘤学随访结果
JACC CardioOncol. 2023 Jan 17;5(1):102-113. doi: 10.1016/j.jaccao.2022.09.006. eCollection 2023 Feb.
2
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.非小细胞肺癌，2022年第3版，美国国立综合癌症网络（NCCN）肿瘤学临床实践指南
J Natl Compr Canc Netw. 2022 May;20(5):497-530. doi: 10.6004/jnccn.2022.0025.
3
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南：执行摘要：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
J Am Coll Cardiol. 2022 May 3;79(17):1757-1780. doi: 10.1016/j.jacc.2021.12.011. Epub 2022 Apr 1.
4
ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis.ALK 抑制剂所致心动过缓：系统评价和荟萃分析。
Lung Cancer. 2021 Nov;161:9-17. doi: 10.1016/j.lungcan.2021.08.014. Epub 2021 Aug 31.
5
Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC.对于晚期ALK重排的非小细胞肺癌患者，洛拉替尼应被视为首选的一线治疗方案。
J Thorac Oncol. 2021 Apr;16(4):532-536. doi: 10.1016/j.jtho.2020.12.021.
6
Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC.对于晚期ALK重排的非小细胞肺癌患者，不应将劳拉替尼视为首选的一线治疗方案。
J Thorac Oncol. 2021 Apr;16(4):528-531. doi: 10.1016/j.jtho.2020.12.022.
7
2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.2018年美国心脏病学会/美国心脏协会/心律学会关于心动过缓和心脏传导延迟患者评估与管理的指南：美国心脏病学会/美国心脏协会临床实践指南工作组和心律学会的报告
J Am Coll Cardiol. 2019 Aug 20;74(7):e51-e156. doi: 10.1016/j.jacc.2018.10.044. Epub 2018 Nov 6.
8
Treating ALK-positive lung cancer--early successes and future challenges.ALK 阳性肺癌的治疗——早期的成功与未来的挑战。
Nat Rev Clin Oncol. 2012 Apr 3;9(5):268-77. doi: 10.1038/nrclinonc.2012.43.